We advised CofounderZone and a group of business angels being the current shareholders of Auxilius Pharma S.A. on their investment into the company made by NanoGroup S.A., FFVC and NCBR IF.
Auxilius Pharma is a biotech company focused on “value-added medicines” (VAM) — i.e., reformulations of known active pharmaceutical substances into new dosage forms that improve efficacy, patient convenience and pharmacokinetic profile. Their lead project (AUX-001) is for the treatment of chronic stable angina, using a new release technology; they plan initial entry via the US market using the FDA 505(b)(2) regulatory pathway.
CofounderZone is a platform connecting experienced entrepreneurs with start-ups. The fund works closely with the Business Angels network it has created, which provides added value through an individual approach to structuring and financing transactions on the private market and uses the substantive potential, contacts and experience of its members. It includes business owners and corporate managers who want to invest their time and capital in developing, innovative companies.
SSK&W provides services to VC funds when investing in technology companies (as part of pre-seed and seed rounds and subsequent rounds, including preIPO), as well as when exiting the investment.
